Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
about
Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial.How I use hydroxyurea to treat young patients with sickle cell anemia.Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia.The role of hydroxyurea in sickle cell disease.Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options.Hydroxyurea therapy mobilises arachidonic Acid from inner cell membrane aminophospholipids in patients with homozygous sickle cell diseaseSickle cell disease: health promotion and maintenance and the role of primary care nurse practitioners.Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension studyPatients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes ClarosParental and other factors associated with hydroxyurea use for pediatric sickle cell diseaseThe pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.Current strategies for the management of children with sickle cell disease.State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome.Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients.
P2860
Q33909764-C36CFCC8-0E49-4546-A94E-0A558E1EA784Q33985120-B6368370-6798-4964-B98C-75A490FEC2E2Q34234885-FB49F023-6EF9-405E-B430-1E8608B5BC0DQ35050928-9E29EF23-9702-4D60-8579-A3F8ADBAFC82Q35076604-AB5F6911-996F-47DC-B96F-0F79C20507A1Q35215166-F60D0A01-C7AB-4785-8172-C4EEB59B8192Q35560041-4F98547F-3C15-4BE9-994D-FD00FA9EAAB6Q35848253-BD37A5FD-E03F-4575-BC51-5B73243A835FQ36462461-F25367B1-FAF2-489E-8D93-B1B018488D05Q36763705-EB47C88C-3427-4109-A171-FFD977D56CB1Q37480741-F6220D92-A1A6-45B2-BDAE-F6EB54CC5858Q37810082-6B82625C-54E5-4E5B-916A-DD6BCE26B002Q43061526-41D5C8D9-E313-40DF-8DB0-0E263BBC49FAQ44758871-FFB80504-A3C5-40C3-9002-994A2E6CD329Q46520558-7F5DC4D5-CA28-4E27-A9E4-79B8581A65A9Q46922191-0C0692D9-5F43-4D55-90C2-B1F12ADDAAE5Q48840343-4FE74079-0C22-4BA7-9B30-2D72BA94A0FE
P2860
Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
@en
type
label
Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
@en
prefLabel
Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
@en
P2093
P1476
Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
@en
P2093
P304
P356
10.1097/00043426-200007000-00009
P577
2000-07-01T00:00:00Z